Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Bristol Myers Squibb Ends Partnership with Cellares Over CAR-T Therapy Manufacturing Challenges.
Aug 25, 2026•about 6 hours ago
Contract Type
partnership
LawrencevilleManufacturingBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
Bristol Myers Squibb has terminated its partnership with cell therapy startup Cellares due to the latter’s inability to meet manufacturing requirements for its CAR-T therapy, Breyanzi. This development highlights the ongoing challenges associated with producing CAR-T therapies, which are crucial for blood cancer treatment.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months
Bristol Myers Squibb signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.